Estimating individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes

Estimating individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes

Background: Intensive glucose control reduces the risk of vascular complications while increasing the risk of severe hypoglycaemia at a group-level. We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes.<br/> Methods: We p...

Full description

Bibliographic Details
Main Authors:	Woodward, M, van der Leeuw, J, Visseren, F, van der Graaf, Y, Grobbee, D, Harrap, S, Heller, S, Mancia, G, Marre, M, Poulter, N, Zoungas, S, Chalmers, J
Format:	Journal article
Published:	Springer 2016

Similar Items

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
by: Mohammedi, K, et al.
Published: (2017)

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
by: Zoungas, S, et al.
Published: (2009)

Intensive glucose lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial
by: Ohkuma, T, et al.
Published: (2019)

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
by: Perkovic, V, et al.
Published: (2013)

History of lower-limb complications and risk of cancer death in people with type 2 diabetes
by: Kamel Mohammedi, et al.
Published: (2021-01-01)

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
by: Patel, A, et al.
Published: (2008)

The impact of level of education on vascular events and mortality in patients with type 2 Diabetes mellitus: results from the ADVANCE study
by: Blomster, J, et al.
Published: (2017)

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
by: Kamel Mohammedi, et al.
Published: (2017-07-01)

Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes
by: Mohammedi, K, et al.
Published: (2016)

Blood pressure variables and cardiovascular risk: new findings from ADVANCE.
by: Kengne, A, et al.
Published: (2009)

Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes
by: Woodward, M, et al.
Published: (2016)

Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study
by: Mohammedi, K, et al.
Published: (2016)

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus
by: Berkelmans, G, et al.
Published: (2019)

Changes in albuminuria and the risk of major clinical outcomes in diabetes: results from ADVANCE-ON
by: Jun, M, et al.
Published: (2017)

Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results From ADVANCE-ON.
by: Jun, M, et al.
Published: (2017)

Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial
by: Selvin, E, et al.
Published: (2019)

Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus: the ADVANCE trial
by: Ohkuma, T, et al.
Published: (2018)

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds
by: Zoungas, S, et al.
Published: (2012)

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
by: Patel, A, et al.
Published: (2007)

The effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
by: Zoungas, S, et al.
Published: (2017)

The relationship between plasma 8-OH-deoxyguanosine and cardiovascular disease and survival in type 2 diabetes: results from the ADVANCE study
by: Thomas, M, et al.
Published: (2018)

Prognostic value of variability in systolic blood pressure related to vascular events and premature death in type 2 diabetes mellitus: The ADVANCE-ON study
by: Ohkuma, T, et al.
Published: (2017)

Self‐rated health scores predict mortality among people with type 2 diabetes differently across three different country groupings: findings from the ADVANCE and ADVANCE‐ON trials
by: Hua, X, et al.
Published: (2020)

Severe Hypoglycemia and Risks of Vascular Events and Death
by: Zoungas, S, et al.
Published: (2010)

Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE‐ON study
by: Rådholm, K, et al.
Published: (2018)

Lowering blood pressure reduces renal events in type 2 diabetes.
by: de Galan, B, et al.
Published: (2009)

Side-effects and tolerability of combination blood pressure lowering according to blood pressure levels – an analysis of the PROGRESS and ADVANCE trials
by: Atkins, A, et al.
Published: (2017)

Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
by: van Steen, S, et al.
Published: (2018)

Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial
by: Glasziou, P, et al.
Published: (2007)

Adverse differences in cardiometabolic risk factor levels between individuals with pre-diabetes and normal glucose metabolism are more pronounced in women than in men: the Maastricht Study
by: de Ritter, R, et al.
Published: (2019)

Associations between body mass index and the risk of renal events in patients with type 2 diabetes
by: Mohammedi, K, et al.
Published: (2018)

Relationship Between Plasma 8‐OH‐Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial
by: Merlin C. Thomas, et al.
Published: (2018-07-01)

Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial
by: Rahman, F, et al.
Published: (2019)

Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: the ADVANCE trial
by: Ohkuma, T, et al.
Published: (2017)

Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
by: Hata, J, et al.
Published: (2013)

Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: The advance trial
by: Hata, J, et al.
Published: (2013)

Intensive glucose control and macrovascular outcomes in type 2 diabetes.
by: Turnbull, F, et al.
Published: (2009)

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
by: Marit de Jong, et al.
Published: (2017-10-01)

Strategies to meet the need for long-term data
by: Chalmers, J, et al.
Published: (2016)

Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis.
by: Clarke, P, et al.
Published: (2010)